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http://dx.doi.org/10.1016/j.ccr.2012.12.020SUMMARYIntegrated genomic analyses revealed a miRNA-regulatory network that further defined a robust integrated
mesenchymal subtype associated with poor overall survival in 459 cases of serous ovarian cancer (OvCa)
from The Cancer Genome Atlas and 560 cases from independent cohorts. Eight key miRNAs, including
miR-506, miR-141, and miR-200a, were predicted to regulate 89% of the targets in this network. Follow-up
functional experiments illustrate that miR-506 augmented E-cadherin expression, inhibited cell migration
and invasion, and prevented TGFb-induced epithelial-mesenchymal transition by targeting SNAI2, a tran-
scriptional repressor of E-cadherin. In human OvCa, miR-506 expression was correlated with decreased
SNAI2 and VIM, elevated E-cadherin, and beneficial prognosis. Nanoparticle delivery of miR-506 in ortho-
topic OvCa mouse models led to E-cadherin induction and reduced tumor growth.INTRODUCTION
Ovarian carcinoma (OvCa) is the most lethal gynecologic malig-
nancy in the United States, with 22,280 new cases and 15,460
deaths estimated for 2012 (Siegel et al., 2012). The high rate of
lethality from OvCa is primarily due to the advanced stage of
disease at diagnosis. Early stage cancers can be cured in upSignificance
Ovarian cancer (OvCa) is one of the most lethal malignancies
sponding molecular driver events is critical for the developmen
lating evidence illustrates that epithelial-mesenchymal transit
driving molecular events are largely unknown. Our studies ide
regulatory network, as an EMT inhibitor in OvCa by targeting
and reduce tumor growth in orthotopic mouse models of OvC
tool for patients with OvCa.
186 Cancer Cell 23, 186–199, February 11, 2013 ª2013 Elsevier Inc.to 90% of patients with current therapies (Bast et al., 2009),
but these rates drop substantially in patients with advanced
disease. Approximately 30% of patients with advanced stage
OvCa survive 5 years after initial diagnosis (Jemal et al., 2004).
Unlike cancers in other organ sites, OvCa can spread by direct
invasion to adjacent organs or by transport throughout the peri-
toneal cavity via peritoneal fluid (Naora and Montell, 2005).in women. Identification of molecular subtypes and corre-
t of new therapies for patients with OvCa. Although accumu-
ion (EMT) plays an important role in OvCa progression, the
ntified and validated miR-506, a key node in the microRNA
SNAI2. Nanoparticle delivery of miR-506 can suppress EMT
a, suggesting miR-506 may serve as a potential therapeutic
Cancer Cell
A Master MicroRNA Network for EMT in OvCaBecause of the diffuse nature of OvCa, surgery alone rarely leads
to complete tumor resection. Postoperative platinum and taxane
chemotherapy is required. Although 70% of patients with OvCa
initially experience a response to therapy, most eventually die of
disease recurrence (Bast et al., 2009; Jemal et al., 2004). A better
understanding of themechanisms involved in OvCa invasion and
more effective therapeutic approaches are urgently needed.
Emerging evidence suggests that acquisition of invasiveness
in OvCa cells is accompanied by the loss of epithelial features
and the gain of a mesenchymal phenotype, a process known
as epithelial-to-mesenchymal transition (EMT) (Cao et al.,
2011; Rosano` et al., 2011). Tothill and colleagues investigated
the gene expression profiles of 285 OvCa cases and reported
that a mesenchymal subtype had relatively poor overall survival
(Tothill et al., 2008). The recent publication by The Cancer
Genome Atlas (TCGA) network recapitulated the mesenchymal
subtype among close to 500 serous histological subtype of
OvCa cases on the basis of transcriptome data (Cancer Genome
Atlas Research Network, 2011). However, there was no correla-
tion between the transcriptomemesenchymal subtype and over-
all survival in the TCGA data set. The driving molecular events
behind the mesenchymal subtype in OvCa are poorly under-
stood and need to be elucidated.
MiRNAs are a class of small noncoding RNA (22 nt) that
regulate gene expression by binding to the 30-untranslated
region (30-UTR) of target genes triggering message RNA
(mRNA) degradation or protein translation inhibition (Bagga
et al., 2005). Almost 1,000 miRNAs have been identified in the
human genome and are thought to regulate 30%of the transcrip-
tome (Esquela-Kerscher and Slack, 2006).Most recently, several
miRNAs, includingmiR-200 family members, have been found to
regulate EMT by targeting E-cadherin repressors ZEB1 and
ZEB2 (Gregory et al., 2008; Park et al., 2008).
In this study, we took an integrated approach and analyzed
multidimensional data from 459 serous OvCa cases in TCGA
to uncover the underlying molecular network of mesenchymal
subtype of ovarian cancer.
RESULTS
Identification of TCGA Mesenchymal Signature Gene
Sets Associated with DNA Copy Number Alterations,
Promoter Methylation, and miRNA Expression
A consensus clustering analysis of expression data among
serous OvCa cases led to the identification of four transcrip-
tional subtypes: differentiated, immunoreactive, proliferative,
and mesenchymal (Cancer Genome Atlas Research Network,
2011). These four subtypes (based solely on mRNA expression)
were not significantly associated with survival differences
(Cancer Genome Atlas Research Network, 2011). We hypothe-
sized that integrating mRNA expression with associated alter-
ations in genomic, epigenetic, and miRNA systems would allow
us to identify molecular driver events and characterize clinically
relevant subtypes.
The mRNA, miRNA, DNA copy number, and DNA methylation
data on 459 clinical annotated OvCa cases were obtained
from TCGA Data Portal (http://tcga-data.nci.nih.gov/tcga/
findarchives.htm). We first identified 2,942 genes that were
significantly overexpressed (FDR < 1%) in the mesenchymalCsubtype relative to other TCGA-defined subtypes. Next, a multi-
variate linear regression model (see Experimental Procedures)
was performed to search for genes whose expression was
correlated with copy number alteration (CNA), DNA methyla-
tion, or associated miRNA expression. This analysis narrowed
the list to 253 genes that were potentially regulated by these
three genetic and epigenetic mechanisms. A set of 219
genes was predicted to be targeted by 19 miRNAs (Figure 1;
see also Table S1 available online). These miRNA-associated
genes included EMT inducers SNAI2 and ZEB2. The well-char-
acterized mesenchymal regulators miR-141 and miR-200a
were among the 19 identified miRNAs. The remaining two
sets represent 26 CNA-associated and nine methylation-
associated genes (Figure 1; Table S1). Twenty-three of the
26 CNA-associated genes, including STAT3, are located in
chromosomal regions 19q13 and 17q11-q21, two regions re-
ported to be frequently deleted in OvCa (Cancer Genome Atlas
Research Network, 2011). The methylation-associated genes
include IL20RA, which is frequently methylated in primary
lung adenocarcinomas and lung cancer cell lines (Tessema
et al., 2008).
MiRNA-Associated Genes Identified a Mesenchymal
Subtype Associated with Poor Overall Survival
The above analysis showed that 259 of the 2,942 TCGA mesen-
chymal subtype-associated genes were correlated with CNA,
methylation, or miRNA alterations. Most of these genes were
members of a miRNA-mRNA regulatory network. We sought to
determine whether the miRNA-associated gene set could be
used to further characterize a mesenchymal subtype in OvCa.
Consensus K-means clustering of 459 OvCa cases, based on
219miRNA-associated genes, identified two clusters (Figure 2A),
with clustering stability decreasing for larger K values (K = 2–6).
Cluster 1, including 172 OvCa cases, formed a tight cluster, with
higher expression of miRNA-associated genes. The majority of
patients with cluster 1 OvCa (98%; 169 of 172 cases) had
advanced stage (stages III and IV) disease (p < 106, two-sided
Fisher’s exact test; Figure 2B; Table S2) and significantly shorter
overall survival durations (p = 0.02, log-rank test; Figure 2B) than
cluster 2 patients in whom miRNA-associated genes were
consistently downregulated. Cluster 1 remained a predictor of
poor patient overall survival (hazard ratio = 0.87, p = 0.058) on
Cox multivariate analysis, after adjusting for patient age and
tumor stage. When only CNA or methylation-associated gene
sets were used, the groups were not clinically distinguishable
(Figures S1B and S1F).
The clustering analysis based on the 219 miRNA-associated
genes was then performed on three independent cohorts (Tothill,
Bentink, and Bonome data sets; Table 1) with 246, 129, and 185
serous OvCa cases, respectively (Bentink et al., 2012; Bonome
et al., 2008; Tothill et al., 2008). In all three data sets, the
miRNA-associated genes characterized two distinct subtypes
that were associated with overall survival (Figures 2C–2H; Table
S2). This suggests the miRNA-associated genes robustly mani-
fest a clinically relevant mesenchymal subtype in serous OvCa.
We designated cluster 1 as the integratedmesenchymal subtype
(iM) and cluster 2 as the integrated epithelial subtype (iE). An
evaluation of hematoxylin and eosin (H&E)-stained tumor tissue
sections from TCGA revealed that iE cases exhibited papillaryancer Cell 23, 186–199, February 11, 2013 ª2013 Elsevier Inc. 187
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Figure 1. Integrated View of Mesenchymal Signature Genes Regulated by Copy Number, Methylation, and MiRNA
Integrated Circos plot shows mesenchymal signature genes regulated by copy number (CN), methylation, and miRNA. An ideogram of a normal karyotype is
shown in the outer ring. The next outermost ring represents copy number as a function of genomic coordinates. (Red represents amplification and green
represents deletion. Dark red and dark green indicate median CN values across all patients, and lighter red and green indicate the 25th and 75th percentiles. The
vertical axis ranges from 1 to +1 on a log2 scale.) The next ring represents the amount of DNA methylation: dark blue indicates the median methylation beta
value, and light blue indicates the 75th percentile. The vertical axis ranges from 0 to 1, and methylation data are averaged using variable-width bins along the
genomic axis (25 CpG probes per bin). In the center of the figure, each arc indicates a predicted regulatory relationship between amiRNA (solid circle) and a gene
(arrow). The colored arcs represent predicted regulation by the eight key miRNAs, whereas the gray arcs represent regulation by the remaining 11 miRNAs.
Outside the ideogram, the miRNAs are colored the same as the corresponding arc. Outside the miRNA, labels are the miRNA-associated genes (red), CNA-
associated genes (green), and methylation-associated genes (blue). Detailed information on each group of genes is listed in Table S1.
See also Figure S1.
Cancer Cell
A Master MicroRNA Network for EMT in OvCaadenocarcinoma with frond-like projections on thin fibrovascular
cores covered by typical cobblestone-like epithelial cells,
resembling fallopian tube epithelium. In contrast, iM cases188 Cancer Cell 23, 186–199, February 11, 2013 ª2013 Elsevier Inc.lacked well-organized epithelial structures, and contained elon-
gated tumor cells and weaker connections between tumor cells,
resembling mesenchymal cells (Figure 2I).
Figure 2. Consensus Clustering Based on 219 miRNA-Associated Genes Identified iM and iE Subtypes
(A, C, E, andG) ConsensusK-means clustering (K= 2) identified two clusters based on the expression levels of 219miRNA-associatedmesenchymal genes in 459
TCGA cases (A), 246 Tothill cases (C), 129 Bentink cases (E), and 185Bonome cases (G). The cases are stratified into iM and iE subtypes as shown by a color code
at the top of the panel (integrated subtype [I-Sub]). Detailed subtype and clinical information is listed in Table S2. For (A), each sample is further labeled in the
middle row of color bands for the TCGA transcriptional subtype (T-Sub).
(B, D, F, and H) Kaplan-Meier overall survival curves for the OvCa iM and iE subtypes in the TCGA (B), Tothill (D), Bentink (F), and Bonome cases (H) data sets. For
(B), the y-axis is log scale and the inserted bar chart shows the distribution of tumor stages in the iM and iE subtypes in the TCGA data set. Cases are categorized
by clinical stages. The number and percentage of tumors in the iM and iE clusters (red, iM; green, iE) are indicated for each stage. Numbers do not add up because
of missing values.
(I) Representative H&E-stained images of iEs and iMs in grade 2 and 3 tumors from the TCGA data set. Scale bar represents 100 mm.
See also Figure S2 and Table S2.
Cancer Cell
A Master MicroRNA Network for EMT in OvCaCompared with the four TCGA-identified transcriptional
subtypes, the iM included nearly all (103 of 105; p < 106,
two-sided Fisher’s exact test; Figure 2A) transcriptional mesen-
chymal subtype cases, as well as 69 cases from other TCGA-
defined subtypes (12, 32, and 25 cases from the proliferative,Cimmunoreactive, and differentiated subtypes, respectively;
Table S2). We evaluated the expression pattern of epithelial
and mesenchymal markers (CDH1 [E-cadherin], FN1, VIM,
SNAI1, SNAI2, and ZEB1) in these 69 iM cases previously
defined as other subtypes solely on the basis of mRNAancer Cell 23, 186–199, February 11, 2013 ª2013 Elsevier Inc. 189
Table 1. Clinicopathologic Information of the OvCa Patient Cohorts
TCGA Tothill Bonome Bentinka Tianjin Bagnoli
Number 459 246 185 129 92 55
Age (SD) 60 (11) 60 (10) 62 (12) 61 (14) 55.5 (12) 56 (12)
Stage
II 23 10 0 1 15 0
III 359 199 144 109 63 45
IV 73 21 41 19 7 10
Tumor Grade
G2 57 88 40 NA 43 7
G3 392 145 144 NA 47 43
Surgical Outcome
Optimal 289 131 90 98 50 24
Suboptimal 114 65 95 28 42 31
Vital Status
Living 203 132 56 56 47 23
Deceased 251 110 129 73 45 32
Follow-Up
Median (range) 31 (1–179) 28 (1–214) 38 (1–164) 31 (1–91) 25 (1–79) 36 (7–91)
Subtype
iE 287 140 102 71 NAb NAb
iM 172 102 83 58 NAb NAb
Source TCGA GSE9891 GSE26712 MTAB386 TCH GSE25204
Numbers do not add up because of missing information in some cases. NA, not applicable; TCH, Tianjin Cancer Hospital.
aFor Bentink Data set, both mRNA and miRNA microarray data are available.
bNo iM/iE subtype was assigned because only miRNA expression data are available.
Cancer Cell
A Master MicroRNA Network for EMT in OvCaexpression data and found that they showed distinct expression
patterns compared with the iE cases in the same transcriptional
subtype (Figure S2A). For instance, in the immunoreactive
subtype, 32 and 67 cases were assigned to the iM and iE
subtypes, respectively. The expression of the mesenchymal
markers SNAI2 and FN1 was significantly upregulated by more
than 2-fold in the 32 iM cases compared with that in the 67 iE
cases in the same immunoreactive subtype (p < 106). Remark-
ably, we observed a significantly poorer overall survival (p = 0.04,
log-rank test; Figure S2B) in the 32 iM cases than in the 67 iE
cases. Similar trends were observed in the proliferative subtype
(Figure S2C). We also assigned the iM/iE subtype classification
for the transcriptional subtypes in the Tothill data set. The 13
iM cases and 32 iE cases in the Tothill ‘‘C2’’ subtype have
enough sample size for us to compare the EMT marker expres-
sion and overall survival duration (Table S2). Similar to our
comparison in TCGA data set, the iM cases showed significant
overexpression in mesenchymal makers (Figure S2E) and
shorter overall survival (p = 0.05, Figure S2F) than the iE cases
in the same C2 subtype. The results suggested that iM/iE
subtype could further classify transcriptional subtypes into clin-
ically relevant groups in multiple data sets.
Key miRNAs’ Regulatory Role in the iM OvCa Subtype
The finding that only 219 miRNA-associated genes character-
ized the poor prognostic mesenchymal subtype strongly
suggested that the OvCa mesenchymal phenotype is likely gov-
erned by a miRNA regulatory network. Of the 19 miRNAs identi-190 Cancer Cell 23, 186–199, February 11, 2013 ª2013 Elsevier Inc.fied in our analysis, eight (miR-25, miR-506, miR-29c, miR-182,
miR-128, miR-101, miR-141, and miR-200a) were predicted to
regulate 89% (195 of 219) of the miRNA-associated genes
(Figures 3A and 3B; Table S3). In addition to having binding sites
in the 30-UTRs of their predicted targets, these eight miRNAwere
also inversely correlated with the expression levels of their pre-
dicted targets (FDR < 0.01, based on linear regression model).
Our analysis showed that miR-141 andmiR-200a regulated 22
and 24 genes (Table S3), respectively, including ZEB2. Both
miR-141 and miR-200a belong to the miR-200 family, and
miRNAs in this family have been demonstrated to prevent EMT
by targeting ZEB1 and ZEB2 in multiple cancer types (Gregory
et al., 2008; Park et al., 2008). Consistently, these two miRNAs
were downregulated in the iM subtype (p < 106, Wilcoxon
rank-sum test; Figure 3C). Besides the miR-200 family, miR-
128 was predicted to target 27 genes (Table S3), and was signif-
icantly downregulated in the iM subtype (p < 103, Wilcoxon
rank-sum test; Figure 3C; Table S4). Previous studies have
also shown that miR-128 inhibits tumor cell migration and inva-
sion in neuroblastoma (Evangelisti et al., 2009).
The three miRNAs predicted to regulate the largest number of
targets are miR-25, miR-506, and miR-29c (regulating 49, 35,
and 32 targets, respectively; Table S3). In nasopharyngeal carci-
nomas, miR-29c has been shown to inhibit metastasis by
targeting SPARC, LAMC1,COL4A1,COL4A2, and other mesen-
chymal markers implicated in invasion and metastasis (Sen-
gupta et al., 2008). These molecules were also predicted to be
targets of miR-29c in our network (Figure 3A; Table S3). Among
Cancer Cell
A Master MicroRNA Network for EMT in OvCathe three miRNAs, miR-506 exhibited the most significant down-
regulation in the iM subtype (p < 2.23 1016, Wilcoxon rank-sum
test; Figure S4A; Table S4). In addition, 35 mesenchymal signa-
ture genes, including the E-cadherin transcriptional repressor
SNAI2 (aka SLUG), were significantly inversely correlated with
miR-506 expression in the 459 TCGA OvCa cases (p = 1.24 3
107 for SNAI2; Figures S4B and S4C).
MiR-506 Promoted the Epithelial Phenotype In Vitro and
Directly Targeted SNAI2
To determine whether forced expression of miR-506 can
promote epithelial phenotype, we transfected SKOV3 cells with
either miR-506 mimic (miR-506) or a scrambled negative micro-
RNA control (miR-Ctrl). MiR-506 overexpression significantly
increased CDH1 mRNA levels, while the mesenchymal markers
SNAI2 and VIM were downregulated by miR-506 (Figure 4A).
Consistently, forced miR-506 expression also increased
E-cadherin and markedly decreased SNAI2 protein expression.
Another mesenchymal marker, N-cadherin, was also downregu-
lated by miR-506 (Figure 4B). These results suggest that cells
with miR-506 overexpression gained an epithelial signature
characterized by E-cadherin expression induction and mesen-
chymal marker suppression.
To further confirm these results, we performed immunofluo-
rescence staining to directly visualize the effect of miR-506 on
E-cadherin expression, localization, and cell morphology. As
shown in Figure 4C, miR-506-transfected SKOV3 cells showed
epithelial cell features, characterized by aggregated cells (Fig-
ure 4C, left panel); immunofluorescence staining revealed that
E-cadherin protein was localized on the membrane at cell-cell
junctions and formed a typical cobblestone structure, indicative
of epithelial cells (Figure 4C). In addition, F-actin distribution was
rearranged to a cortical pattern, which is another hallmark of the
epithelial phenotype (Figure 4C). In contrast, the cells trans-
fected with miR-Ctrl showedmesenchymal phenotype indicated
by an absence of E-cadherin on the cell membrane and rear-
rangement of F-actin from a cortical to a stress-fiber pattern (Fig-
ure 4C). In addition, ectopic miR-506 expression decreased cell
migration compared with miR-Ctrl transfected cells, as indicated
by a wound-healing assay (Figure 4D). An invasion assay re-
vealed similar results, in which miR-506 expression significantly
decreased invaded cell numbers by more than 5-fold compared
with in miR-Ctrl-transfected cells (Figure 4E).
E-cadherin is a critical protein that determines epithelial cell
phenotype, and lack of E-cadherin is believed to be a driving
event for EMT and cancer invasion and metastasis (Thiery
et al., 2009). E-cadherin is regulated by a number of transcription
factors, including the repressor SNAI2 (Peinado et al., 2007).
TargetScan predicted three miR-506 binding sites in the
30-UTR of the SNAI2 gene (Figure 4F). Our computational and
functional study results provided evidence that miR-506 down-
regulated SNAI2 and upregulated E-cadherin. We performed
luciferase reporter assay to examine whether miR-506 directly
targeted SNAI2. We cloned the 30-UTR of SNAI2 into the
pGL3-ctrl vector and generated pGL3-SNAI2 constructs.
Cotransfection of pGL3-SNAI2 and miR-506 resulted in a
72.2% reduction in luciferase activity compared with that after
cotransfection with miR-Ctrl, suggesting that miR-506 directly
targets SNAI2 (Figure 4F). To further confirm that miR-506Cspecifically regulates SNAI2 through the predicted binding sites,
we generated the control construct-pGL3-SNAI2-Mu, in which
the miR-506 binding site sequences on the 30-UTR of SNAI2
were deleted. We then cotransfected this construct with miR-
506 mimic or miR-Ctrl into cells. We observed that deletion of
the miR-506 binding sites from the 30-UTR of SNAI2 abolished
the effect of miR-506 on luciferase activity (Figure 4F). To deter-
mine whether miR-506’s inhibition of EMT was mediated by
SNAI2, we established SKOV3 cells overexpressing SNAI2
from expression vector without the 30-UTR (Figures S4D and
S4E). As shown in Figure S4F, SKOV3 cells overexpressing
SNAI2 had decreased expression of E-cadherin protein and ex-
hibited elongated mesenchymal cell morphology. In contrast,
knockdown of SNAI2 by three different siRNAs led to increased
E-cadherin protein levels and typical cobblestone epithelial cell
morphology (Figures S4G). Notably, overexpression of SNAI2
abolished miR-506’s induction of E-cadherin (Figure 4G). These
results confirmed that miR-506 specifically targeted the 30-UTR
of SNAI2 and thus inhibited SNAI2 gene expression, leading to
E-cadherin upregulation.
MiR-506 Blocked Transforming Growth Factor
b-Induced EMT In Vitro
Previous studies have established that transforming growth
factor-b (TGFb) is a robust inducer of EMT in multiple cell types
(Zhu et al., 2010). Consistent with these findings, our pathway
analysis revealed that the TGFb pathway was significantly upre-
gulated in iM subtypes (p < 106; Figure S5; Table S5). Conse-
quently, we sought to determine whether miR-506 affected
TGFb-induced EMT in OvCa cells. We treated OVCA420 and
OVCA433 cells with TGFb after transfecting miR-506 or miR-
Ctrl. In miR-Ctrl-transfected OVCA420 cells, TGFb treatment
induced SNAI2 by 6-fold and suppressed CDH1 expression by
2-fold at the mRNA level (p < 0.05, Figure 5A). In contrast,
miR-506 overexpression abolished TGFb-induced alterations
of EMT markers (Figure 5A).
We next performed immunofluorescence staining to evaluate
the morphologic changes in these cells. After TGFb treatment,
OVCA420 cells transfected with miR-Ctrl underwent a morpho-
logic change characterized by elongated cells, amarked spread-
ing growth pattern together with an absence of E-cadherin on the
cell membrane and strong F-actin stress fibers, suggesting
augmented mesenchymal features compared with untreated
cells (Figure 5B). In contrast, miR-506 transfection blocked the
TGFb-inducedmesenchymal phenotype, promoting an epithelial
phenotype characterized by E-cadherin localization at cell-cell
junctions and cortical F-actin staining (Figure 5B). Consistently,
miR-506 treatment blocked TGFb-induced invasion (Figure 5C).
Similar results were also observed in OVCA433 cells (Figures
5D–5F).
MiR-506 Expression Was Associated with Increased
E-Cadherin, Decreased SNAI2 and VIM, and Longer
Overall Survival Duration in Serous OvCa
While the TCGA database allowed us to evaluate the association
between miR-506 and CDH1 and SNAI2 mRNA levels, protein
level data were not available in this data set. To further investi-
gate this proposed regulation in OvCa samples, we acquired
a cohort of 92 clinically annotated serous OvCa tumor samplesancer Cell 23, 186–199, February 11, 2013 ª2013 Elsevier Inc. 191
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Cancer Cell
A Master MicroRNA Network for EMT in OvCafrom Tianjin Cancer Hospital (TCH). In this cohort, the median
follow-up duration was 25 months (range, 1–79 months).
Fifty-one percent of patients were alive at the last follow-up.
The median overall survival duration of the cohort was similar
to those in the TCGA and Tothill data sets. Detailed clinical infor-
mation was described in Table S6.MiR-506 wasmeasured using
real-time RT-PCR analysis in frozen tissues and miRNA in situ
hybridization on tissue microarrays (TMAs) of formaldehyde-
fixed, paraffin-embedded tissues from the same patients. Both
methods revealed consistent results for miR-506 expression
(Figures 6A and 6B). At the same time, we performed H&E and
immunohistochemical staining for SNAI2, E-cadherin, and VIM
on the TMAs. Consistent with our observations from TCGA
samples, tumors with low miR-506 expression exhibited a
more mesenchymal phenotype, with elongated tumor cells and
weaker connections between tumor cells, whereas those with
high miR-506 expression exhibited more epithelial characters,
such as displaying a papillary structure with frond-like pro-
jections on thin fibrovascular cores covered by typical cobble-
stone-like epithelial cells (Figure 6A). Moreover, miR-506 expres-
sion was inversely correlated with SNAI2 and VIM protein
expression (p = 0.008 and 0.03, respectively) and positively cor-
related with E-cadherin protein expression (p = 0.004) (Figures
6A and 6B). Remarkably, high miR-506 expression was signifi-
cantly correlated with longer overall survival in the univariate
model (log-rank p = 0.045, Figure 6C) and multivariate model
(hazard ratio = 0.72, p = 0.05). In TCGA data, the patients with
high miR-506 and low SNAI2 expression have significantly
longer overall survival and progression free survival (Figures
S4H and S4I) compared to those with low miR-506 and high
SNAI2 expression. To further confirm miR-506’s association
with good prognosis in ovarian cancer, we obtained twomiRNAs
microarray data sets from GEO and ArrayExpress (Bentink Data
set and Bagnoli Data set, Table 1) with 129 and 55 OvCa cases,
respectively. In both data sets, miR-506 expression is signifi-
cantly associated with longer progression-free survival (log-
rank p = 0.02 and 0.0006 for Bentink and Bagnoli Data sets,
respectively, Figures 6D and 6E).
Next, we sought to explore themechanisms for the attenuated
expression of miR-506 in patients with poor clinical outcome.
Integrated analysis of copy number and miRNA expression
data in TCGA showed miR-506 expression was not associated
with copy number alterations. Interestingly, we performed a
demethylation experiment by treating ovarian cancer cells with
5-azaC and found an induction of miR-506 (Figure S6A). To
more directly evaluate themethylation status of themiR-506 pro-
moter in serous OvCa patient tumors, we identified five CpG
sites in the promoter region of miR-506 (Figure S6B). Although
the TCGA methylation microarray does not contain the five sites
that would allow us to directly evaluate the methylation status of
themiR-506 promoter in the TCGA data, we performed quantita-
tive pyrosequencing following sodium bisulfite treatment of(B) A histogram reveals the number of predicted targets for each of the 19 miRN
(C) The association between key miRNA expression and clinical information, as
significance of differential expression between iM and iE subtypes, as estimated
the significance of miRNA expression’s association with clinical stage, as estimat
expression’s association with overall survival (OS), as estimated using the Cox p
See also Figure S3 and Table S3.
CDNAs isolated from the ovarian cancer tissues in the Tianjin
cohort. Our results showed that among the five methylation sites
we interrogated, two displayed trends of negative correlation
between methylation and miR-506 expression (p = 0.06 and
0.15 for sites 5 and 1, respectively, Figure S6C).
Systematic Delivery of miR506 Inhibited SNAI2 and VIM
and Induced E-Cadherin expression in vivo
To further verify miR-506’s role and to determine the therapeutic
efficacy of miR-506, we established OvCa orthotopic mouse
models using two serous OvCa cell lines (SKOV3-IP1 and
HeyA8-IP1, see Experimental Procedures for details). These
two sublines were generated from ascites developed in nu/nu
mouse by administering an intraperitoneal injection of SKOV3
and HeyA8, as described previously (Xu et al., 1999). For both
models, delivery of miR-506 incorporated in DOPC nanolipo-
somes (miR-506-DOPC) resulted in a significant reduction in
the number of tumor nodules (75% reduction in HeyA8-IP1;
p = 0.009 and 48% reduction in SKOV3-IP1; p = 0.01; Figures
7A and 7B) and tumor weight (78% reduction in HeyA8-IP1,
p = 0.004; and 53% reduction in SKOV3-IP1, p = 0.01; Figure 7C)
compared with miR-Ctrl. We further performed immunohisto-
chemical staining of SNAI2, E-cadherin, and VIM in the tumors
to determine whether systemic delivery of miR-506 affected
the expression of these EMTmarkers. For eachmodel, represen-
tative sections with the staining of SNAI2, E-cadherin, and VIM
were shown (Figure 7D). Compared with miR-Ctrl, miR-506
treatment significantly suppressed SNAI2 (58% reduction
in HeyA8-IP1 and 68% reduction in SKOV3-IP1 models; p <
0.05, Figure 7E) and VIM (30% reduction in both models, p <
0.05, Figure 7E), and significantly induced E-cadherin (200%
induction in HeyA8-IP1 and 120% induction in SKOV3-IP1; p <
0.05, Figure 7E). These results showed that nanoparticle delivery
of miR-506 may serve as a potential therapeutic intervention for
OvCa.
DISCUSSION
Using integrated approaches, we uncovered a key miRNA-regu-
latory network that reproducibly defines the iM subtype robustly
associated with poor overall survival of women with serous
OvCa. Extensive functional studies characterized miR-506 as
a potent EMT inhibitor and a potential therapeutic tool, which
may have an impact on improving treatment for one of the
most aggressive cancer types among women.
Genomic and molecular profiling has revealed that even within
the same anatomical location and histological classification,
cancer is heterogeneous (Ein-Dor et al., 2005). Efforts from
systematic studies such as TCGA have allowed comprehensive
molecular classification of cancer by integrated analyses of
multidimensional data from a large cohort of clinical samples
at both genomic and epigenetic levels (Noushmehr et al., 2010;As.
well as miRNAs’ putative functional targets in terms of EMT inhibition. %, The
by the Wilcoxon signed-rank test. Detailed information is listed in Table S4; @,
ed using Spearman’s rank correlation coefficient; #, the significance of miRNA
roportional hazards model; *, reported by (Carvalho et al., 2012).
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Figure 4. Overexpression of miR-506 in OvCa Cells Is Sufficient to Induce Epithelial Phenotype
(A) Changes in microRNA and mRNA levels in SKOV3 cells transfected with miR-506 or control miRNA (miR-Ctrl) as measured by real-time RT-PCR (TaqMan).
Two independent time course experiments were performed; the average ± standard error (indicated by the error bars) of the two experiments were shown.
(B) Western blotting analysis of epithelial and mesenchymal markers in SKOV3 cells transfected with miR-506 or control miRNA (miR-Ctrl) from the same
transfection as in (A). OVCA433 cell lysate was used as the positive control for the epithelial marker E-cadherin. One mesenchymal marker, N-cadherin (N-cad),
was measured on a different blot. Both blots were re-probed with actin to control for protein loading.
(C) Inverse phase microscopy (left panel) and E-cadherin and F-actin staining (right panels) of SKOV3 cells transfected with miR-506 or control miRNA (miR-Ctrl)
for 72 hr. Cell nuclei were stained with DAPI. Scale bars represent 50 mm.
(D) Wound healing assay. Cells from the same transfection as in (C) were seeded into the m-dish 35mm, high culture-insert and a woundwas applied at 48 hr post-
transfection.
(E) In vitro invasion assay Cells from the same transfection as in (C) were seeded into triplicate mitrigel coated invasion chambers at 48 hr post- transfection and
allowed to invade toward serum for 22 hr. The invading cell numbers on each filter were counted and data were plotted in fold change by defining the number from
miR-506-transfected cells as 1. Error bars represent ± SD.
(F) The relative luciferase activities were shown from three independent experiments (upper panel). The pGL3-SNAI2 reporter gene has the full length of SNAI2
30-UTR cloned into pGL3- control vector. The pGL3-SNAI2-Mu vector has the three miR506 binding sites deleted and confirmed by sequencing. SKOV3 cells
were transfected with pGL3-SNAI2 or pGL3-SNAI2-Mu, respectively, together with miR-506 mimics or mimic negative control. The three predicted binding sites
of miR-506 were shown in the SNAI2 30-UTR region (lower panel). Error bars represent ± SD.
(G) Overexpression of SNAI2 from expression vector without 30-UTR abrogatesmiR-506’s induction of E-cadherin. Two SKOV3-SNAI2 stable clones (S7 and S11)
and empty vector stable cells (EV) were transfected with miR-506. Whole cell lysate from each sample was collected at 72 hr post-transfection and subjected for
western blot. For comparison, the levels of E-cadherin and SNAI2 in the EV cells transfected with mimic negative control (miR-ctrl) for 72 hr were shown.
See also Figure S4.
Cancer Cell
A Master MicroRNA Network for EMT in OvCa
194 Cancer Cell 23, 186–199, February 11, 2013 ª2013 Elsevier Inc.
Figure 5. Overexpression of miR-506 Alone in OvCa Cells Is Sufficient to Inhibit TGFb-Induced EMT
(A and D) Quantification by real-time RT-PCR (TaqMan) of CDH1 and SNAI2 in OVCA420 (A) and OVCA433 (D) cells transfected with miR-506 or control miRNA
(miR-Ctrl). At 24 hr post-transfection, the cells were cultured in serum-free medium containing TGFb1 for 48 hr. Data were means of triplicate PCR assays and
presented relative to the mRNA levels in OVCA420 (A) and OVCA433 (D) cells, respectively. *p < 0.05.
(B and E) Inverse phase microscopy (left panel) and E-cadherin and F-actin staining (right panels) of OVCA420 (B) and OVCA433 (E) cells from the same
transfection and treated the same way as described above. Cell nuclei were stained with DAPI and scale bars represent 50 mm.
(C and F) In vitro invasion assay of theOVCA420 (C) andOVCA433 (F) cells from the same transfection as described previously. At 24 hr post-transfection the cells
were cultured in serum-free medium with TGFb1 for 24 hr and then were seeded into triplicate invasion chambers in serum-free medium containing TGFb1. The
cells were allowed to invade toward serum for 22 hr. The invading cell numbers on each filter were counted and data were plotted in fold change by defining the
number from miR-Ctrl-transfected cells as 1. Error bars represent ± SD. ***p < 0.001.
See also Figure S5.
Cancer Cell
A Master MicroRNA Network for EMT in OvCaYang et al., 2011). The current study shows that our integrated
approach is a major step forward compared to the commonly
used transcriptome-based approaches, which have resulted in
inconsistent clinical associations from different data sets
(Cancer Genome Atlas Research Network, 2011; Tothill et al.,
2008). Specifically, integrated analysis of miRNAs and transcrip-
tome further grouped the transcriptional subtypes into more
clinically relevant iM and iE subtypes. The strength of this inte-
grated approach is that it also reveals regulatory mechanisms
associated with the subtypes. In particular, our integrated anal-
ysis of OvCa highlights the important role of a miRNA regulatory
network consisting of eight key miRNAs for the mesenchymal
subtype. MiR-141 and miR-200, among the eight key miRNAs,
have been reported to be EMT regulators (Gregory et al., 2008;
Park et al., 2008). Other key miRNAs, such as miR-29c, miR-
101, andmiR-128 have also been shown to regulate EMT-related
processes (e.g., cell adhesion, cytoskeleton organization, and
extracellular matrix molecular function) (Evangelisti et al., 2009;
Varambally et al., 2008). We subsequently narrowed our focus
on the function of miR-506 because it was the least studied
among the miRNA network.CMiR-506 is located in Xq27.3, a chromosomal region associ-
ated with the ‘‘fragile X syndrome.’’ Female patients with fragile
X syndrome suffer from primary ovarian insufficiency (Santoro
et al., 2012). The region has also been identified as a high
susceptibility locus in linkage studies of familial testicular germ
cell tumors (Rapley et al., 2000). Downregulation of miR-506
has been observed in kidney cancer (Zhou et al., 2010) and
chemical carcinogen-transformed lung cancer (Zhao et al.,
2011), suggesting that miR-506 potentially plays a role in tumor
suppression.
SNAI2 (also known as Slug) is one of the three zinc finger tran-
scription factors of the Snail family, which in recent years has
been shown to be a major regulator of EMT (Peinado et al.,
2007). In experimental models of ovarian carcinoma, SNAI2
was shown to induce EMT by repressing E-cadherin, and to
promote tumor growth and invasion (Kurrey et al., 2005). In addi-
tion, it was reported that treatment of cultured ovarian surface
epithelium (OSE) by TGFb induces an EMT-like process, charac-
terized by the inability to form an epithelial barrier, with an
increase in SNAI2 level and decrease of E-cadherin. However,
TGFb treatment did not increase expression in TWIST1 andancer Cell 23, 186–199, February 11, 2013 ª2013 Elsevier Inc. 195
Figure 6. Correlation between miR-506 and
SNAI2, E-cadherin, and VIM Expression
and Prognosis in Multiple Serous OvCa
Cohorts
(A) Representative images of in situ hybridization
staining for U6 snRNA (positive control) and miR-
506 and immunohistochemical staining for SNAI2,
E-cadherin (E-cad), and vimentin (VIM) in low and
high miR-506 expression cases. The low and high
miR-506 expression was stratified by using
average of miR-506 PCR expression as threshold.
Scale bar represents 100 mm.
(B) Bar charts show the association between
miR-506 expression and SNAI2, E-cadherin, and
VIM expression. The low and high miR-506 ex-
pression is based on average value of miR-506
PCR expression. The x-axes represent miR-506
expression, as measured by in situ hybridization,
and SNAI2, E-cadherin (E-cad), and vimentin (VIM)
expression, as indicated by immunohistochemical
staining. Error bars represent ± SD. *p < 0.05
** < 0.01.
(C) Kaplan-Meier overall survival curves in miR-
506 low and high expression OvCa cases. The low
and high miR-506 expression is based on average
value of miR-506 PCR expression.
(D and E) Kaplan-Meier progression-free survival
curves in miR-506 low and high expression (ac-
cording to average of miR-506 expression) in 129
Bentink cases (D) and 55 Bagnoli cases (E).
See also Figure S6.
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A Master MicroRNA Network for EMT in OvCaZEB1 (Zhu et al., 2010), suggesting that SNAI2 plays an
essential role in ovarian EMT. In this study, we demonstrate
that miR-506 is a potent inhibitor of themesenchymal phenotype
and TGFb-induced EMT by directly targeting SNAI2. We estab-
lished the importance of the miR-506-SNAI2 axis by rescue
experiment and the reverse correlation between miR-506
and SNAI2 expression in tumor samples from multiple patient
cohorts.
Our observation suggests miR-506 is partially regulated by
methylation. This is consistent with a recent large-scale screen-
ing of epigenetic regulated miRNAs in OvCa, which showed the
Xq27.3 miRNA cluster (including miR-506) was regulated by
epigenetic mechanisms (Zhang et al., 2008). Interestingly, recent196 Cancer Cell 23, 186–199, February 11, 2013 ª2013 Elsevier Inc.studies showed that other EMT inhibitory
miRNAs including miR-200 are also
subject to negative regulation bymethyla-
tion. In lung cancer, epigenetically
silenced miR-200-mediated EMT is likely
an early event in carcinogen-induced
transformation of human lung epithelial
cells (Tellez et al., 2011). Further studies
using larger sample sizes are needed to
reveal the relationship between miR-506
methylation and miR-506 expression.
Besides indicating the function and
mechanism of miR-506 in EMT, our study
explored the potential therapeutic value
of miR-506 for OvCa. Introduction of
miRNAs in vitro is well known to be highlyefficient. However, delivery of miRNAs in vivo ismuchmore chal-
lenging (Garzon et al., 2010). Although the initial proof-of-
principle studies using miRNAs as therapeutics took advantage
of adenoviral-based (Esquela-Kerscher et al., 2008) and lentivi-
ral-based (Trang et al., 2010) delivery vehicles, translation into
clinical practice requires the development of safer delivery
methods (Pecot et al., 2011; Rupaimoole et al., 2011). Packaging
mature miRNAs into lipid-based nanoparticles (neutral or
charged) that can be systemically or specifically delivered to
the tumor microenvironment has been shown to successfully
transfer miRNAs and therapeutically regulate their targets in
the lung (Wiggins et al., 2010), pancreas (Pramanik et al.,
2011), and prostate (Liu et al., 2011). In this study, we
Figure 7. miR-506 Inhibits Tumor Progres-
sion in the OrthotopicMouseModel of OvCa
(A) Representative images of tumor nodules and
H&E staining of tumors in control miRNA- andmiR-
506-treated mice (HeyA8-ip1). Scale bar in the
upper panel represent 1 cm. Scale bar in the lower
panel represents 100 mm.
(B and C) Quantification of tumor weights (B) and
tumor nodules (C) in control and miR-506 treated
mice (n = 10 for each group) that were injected
intraperitoneally with HeyA8-ip1 (HeyA8) and
SKOV3-ip1 (SKOV3) ovarian cancer cells, re-
spectively. Error bars represent ± SD.
(D) HeyA8-ip1 and SKOV3-ip1 tumor samples from
control and miR-506 treated mice were stained for
SNAI2, VIM and E-cad by immunohistochemistry.
Scale bar represents 100 mm.
(E) Quantification of SNAI2, VIM and E-cad protein
expression. Error bars represent standard errors.
*p < 0.05. Error bars represent ± SD.
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A Master MicroRNA Network for EMT in OvCaillustrated that nanoparticle-delivery of miR-506 effectively sup-
pressed tumor growth in two orthotopic ovarian cancer models.
EMT of the resulting treated tumors was blocked based on the
examination of EMT markers. Although we have not examined
whether the delivery of miR-506 will sensitize ovarian cancers
to chemotherapy in our preclinical model, a recent study demon-
strated that an OvCa cell line that stably expresses miR-141 or
miR-200a shows better response to chemotherapy in a sub-
cutaneous xenograft OvCa mouse model (Mateescu et al.,
2011). Future studies are needed to validate the clinical value
of miR-506 in OvCa treatment.
In summary, our integrated analyses have identified a master
microRNA regulatory network for the mesenchymal subtype in
serous ovarian cancer. Nanoparticle delivery of the miR-506,Cancer Cell 23, 186–199,one of the key miRNAs in the network,
may represent an important strategy for
the treatment of the most aggressive
ovarian cancers.
EXPERIMENTAL PROCEDURES
Patients and Data Collection
Agilent Human Genome comparative genomic
hybridization microarray 1x1M copy number
data, Agilent 244K gene expression data, Agilent
human miRNAmicroarray 83 15KmiRNA expres-
sion data, Illumina Infinium methylation data, and
clinical information were obtained from the open-
access and controlled-access tiers of the TCGA
data portal, with NIH approval. Alignment of
sample identifiers yielded 459 tumor cases, with
all information available at the time of data retrieval
from the TCGA. The Tothill, Bentink, Bonome, and
Bagnoli data sets were downloaded from the Gene
Expression Omnibus and ArrayExpression data-
bases (Table 1). Frozen and paraffin-embedded
tissues from 92 OvCa cases were collected from
Tianjin Medical University Cancer Institute and
Hospital, with approval of the institutional review
board. Informed consent has been obtained from
patients. All patients had been treated with
a combination of surgery and platinum-basedchemotherapy. The detailed clinical characteristics for each patient in the
Tianjin cohort are listed in Table S6.
Identification of Integrated Mesenchymal Gene Signatures
A linear regression model was used to analyze the expression level of each
mesenchymal signature gene. The associated gene copy number, promoter
methylation probes, and miRNA expression level (see Supplemental Experi-
mental Procedures) were chosen as regulatory factors for each gene and
designated as independent variables in the regression model. For each regu-
latory factor in the model, a regression coefficient was estimated, reflecting its
influence on gene expression. Sample labels were randomly permuted 1,000
times to generate a background distribution of regression coefficients, and
a threshold was used (FDR = 0.01) to define the significant regulatory factors
for each gene. A refined subset of mesenchymal signature genes was then
selected according to two criteria: (1) each gene was significantly regulated
by one or more factors on the basis of the regression model, and (2) theFebruary 11, 2013 ª2013 Elsevier Inc. 197
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A Master MicroRNA Network for EMT in OvCasignificant regulatory factor itself was also significantly altered (FDR < 1%)
between the mesenchymal subgroup and other subgroups. We termed this
integrative analysis algorithm as MIRACLE (Master mIRna Analysis for Cancer
moLecular subtypE). The miRNA target information was from TargetScan
(Lewis et al., 2003).
Statistical and Clustering Analysis
Student’s t test, analysis of variance, chi-square, Wilcoxon rank-sum test,
Fisher’s exact test, Kaplan-Meier estimate, and Mantel-Cox survival analyses
were performed using R 2.10.0. Significance was defined as p < 0.05.
Benjamini-Hochberg multiple testing correction (Benjamini and Hochberg,
1995) was used to estimate the FDR when multiple testing correction was
applied. Consensus clustering was performed as in previous studies (Noush-
mehr et al., 2010; Verhaak et al., 2010). Increasing values of K (2 through 6,
inclusive) were used to identify optimal segregation. For each K, 1,000 random
iterations were performed to characterize the clusters.
Animals, Orthotopic In Vivo Model, and Tissue Processing
Forty female athymic nude mice were purchased from the National Cancer
Institute, Frederick Cancer Research and Development Center (Frederick,
MD) and were cared for according to guidelines set forth by the American
Association for Accreditation of Laboratory Animal Care and the U.S. Public
Health Service policy on Human Care and Use of Laboratory Animals. All
mouse studies were approved and supervised by the MD Anderson Cancer
Center Institutional Animal Care and Use Committee. All animals were
8–12 weeks of age at the time of injection. HeyA8-ip1 and SKOV3-ip1 cells
were trypsinized, washed, and resuspended in Hanks’ balanced salt solution
(GIBCO, Carlsbad, CA) and injected into the peritoneal cavities of mice
(HeyA8IP1 or SKOV3IP1: 1.0 3 106 cells/animal). Seven days after tumor
cell injection, mice were randomly separated into two groups (n = 10 mice
per group) and treated with miRNA incorporated in DOPC nanoliposomes
(intraperitoneal administration)—control miRNA/DOPC or miR-506/DOPC for
each cell line (see Supplemental Experimental Procedures for detailed method
of liposomal preparation). Twice-weekly treatments continued for 4–6 weeks.
All mice in the experiment were then killed and necropsied, and their tumors
were harvested. Tumor weights, numbers, and locations were recorded.
Mean mouse body weights were similar among groups, suggesting that
feeding and drinking habits were not affected. Tumor tissue was snap frozen
or fixed in formalin. H&E and immunohistochemical staining were performed
on formalin-fixed, paraffin-embedded slides (see Supplemental Experimental
Procedures).
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, six tables, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.ccr.2012.12.020.
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